



Missouri Pharmacy Program – Preferred Drug List



Anticoagulant Agents – Oral and Subcutaneous

Effective 07/05/2012
Revised 01/09/2020

Preferred Agents

- Eliquis®
- Enoxaparin
- Fragmin®
- Pradaxa®
- Warfarin
- Xarelto® 10, 15, 20mg
- Xarelto® Starter Pack

Non-Preferred Agents

- Arixtra®
- **Bevyxxa®**
- Coumadin®
- Fondaparinux
- Jantoven®
- Lovenox®
- Savaysa®
- **Xarelto® 2.5mg**

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 3 or more preferred agents
 - Documented trial period for preferred agents **OR**
 - Documented ADE/ADR to preferred agents **OR**
- Documented compliance on current therapy regimen
- Appropriate diagnosis: Factor Xa Inhibitors, Direct Thrombin Inhibitors, Warfarin

Generic	Brand	Indication
Apixaban ³	Eliquis®	<ul style="list-style-type: none"> • Prevention of stroke and systemic embolism with nonvalvular atrial fibrillation³ • DVT prophylaxis after hip replacement³ • DVT Prophylaxis after knee replacement³ • Treatment of DVT and PE³ • Prevention of recurrent DVT and/or PE³
Dabigatran	Pradaxa®	<ul style="list-style-type: none"> • Prevention of stroke and systemic embolism with nonvalvular atrial fibrillation • DVT prophylaxis after hip replacement • Treatment of DVT and PE¹ • Prevention of recurrent DVT and/or PE
Edoxaban ⁴	Savaysa®	<ul style="list-style-type: none"> • Prevention of stroke and systemic embolism with nonvalvular atrial fibrillation⁴ • Treatment of DVT and PE^{1,4}
Fondaparinux	Arixtra®	<ul style="list-style-type: none"> • DVT prophylaxis after hip replacement • DVT Prophylaxis after knee replacement • Treatment of DVT and PE • Prevention of recurrent DVT and/or PE
Rivaroxaban ³	Xarelto®	<ul style="list-style-type: none"> • Prevention of stroke and systemic embolism with nonvalvular atrial fibrillation³ • DVT prophylaxis after hip replacement³ • DVT Prophylaxis after knee replacement³

Generic	Brand	Indication
		<ul style="list-style-type: none"> • Treatment of DVT and PE³ • Prevention of recurrent DVT and/or PE³
Warfarin	Coumadin®	<ul style="list-style-type: none"> • Prevention of stroke and systemic embolism with nonvalvular atrial fibrillation • DVT prophylaxis after hip replacement • DVT Prophylaxis after knee replacement • Treatment of DVT and PE¹ • Prevention of recurrent DVT and/or PE • Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement² • Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events after MI
Betrixaban ⁵	Bevyxxa®	<ul style="list-style-type: none"> • VTE prophylaxis in adult patients hospitalized for acute medical illness who are at risk due to restricted mobility or other risk factors for VTE⁵

1 Requires initial 5-10 day therapy with a parenteral anticoagulant

2 Atrial fibrillation due to any etiology

3 Tablets may be crushed and taken by mouth or via nasogastric tube or gastric feeding tube

4 Edoxaban should not be used in patients with creatinine clearance >95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied. Creatinine clearance should be assessed before starting edoxaban for the treatment of non-valvular atrial fibrillation.

5 Safety and efficacy not established in patients with prosthetic heart valves

- Appropriate diagnosis: Low Molecular Weight Heparins (LMWH's)

Generic	Brand	Indication
Dalteparin	Fragmin®	<ul style="list-style-type: none"> • Prophylaxis of DVT which may lead to PE in abdominal surgery and at risk for thromboembolic complications • Prophylaxis of DVT which may lead to PE in hip replacement surgery • Prophylaxis of DVT which may lead to PE in severely restricted mobility during acute illness • Prophylaxis of ischemic complications in unstable angina and non-Q wave MI⁸ • Extended treatment of symptomatic VTE (proximal DVT and/or PE) in cancer patients to reduce recurrence of VTE
Enoxaparin	Lovenox®	<ul style="list-style-type: none"> • Prophylaxis of DVT which may lead to PE in abdominal surgery and at risk for thromboembolic complications • Prophylaxis of DVT which may lead to PE in hip replacement surgery⁶ • Prophylaxis of DVT which may lead to PE in knee replacement surgery • Prophylaxis of DVT which may lead to PE in severely restricted mobility during acute illness • Treatment of acute DVT with or without PE⁷ • Prophylaxis of ischemic complications in unstable angina and non-Q wave MI⁸ • Treatment of acute ST-segment elevation myocardial infarction [STEMI] managed medically or with subsequent percutaneous coronary intervention⁸

6 During and following hospitalization

7 Approved for *inpatient* treatment of acute DVT *with or without PE* when administered in conjunction with warfarin; approved for *outpatient* treatment of DVT *without PE* when administered in conjunction with warfarin

8 In conjunction with ASPIRIN

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if no approval criteria are met

- Drug Prior Authorization Hotline: (800) 392-8030